Controversies in orthopaedic oncology

Bone Joint J. 2024 May 1;106-B(5):425-429. doi: 10.1302/0301-620X.106B5.BJJ-2023-1381.


Chondrosarcoma is the second most common surgically treated primary bone sarcoma. Despite a large number of scientific papers in the literature, there is still significant controversy about diagnostics, treatment of the primary tumour, subtypes, and complications. Therefore, consensus on its day-to-day treatment decisions is needed. In January 2024, the Birmingham Orthopaedic Oncology Meeting (BOOM) attempted to gain global consensus from 300 delegates from over 50 countries. The meeting focused on these critical areas and aimed to generate consensus statements based on evidence amalgamation and expert opinion from diverse geographical regions. In parallel, periprosthetic joint infection (PJI) in oncological reconstructions poses unique challenges due to factors such as adjuvant treatments, large exposures, and the complexity of surgery. The meeting debated two-stage revisions, antibiotic prophylaxis, managing acute PJI in patients undergoing chemotherapy, and defining the best strategies for wound management and allograft reconstruction. The objectives of the meeting extended beyond resolving immediate controversies. It sought to foster global collaboration among specialists attending the meeting, and to encourage future research projects to address unsolved dilemmas. By highlighting areas of disagreement and promoting collaborative research endeavours, this initiative aims to enhance treatment standards and potentially improve outcomes for patients globally. This paper sets out some of the controversies and questions that were debated in the meeting.

Publication types

  • Consensus Development Conference

MeSH terms

  • Antibiotic Prophylaxis
  • Bone Neoplasms* / surgery
  • Bone Neoplasms* / therapy
  • Chondrosarcoma* / therapy
  • Humans
  • Medical Oncology
  • Orthopedics
  • Prosthesis-Related Infections / etiology
  • Prosthesis-Related Infections / therapy
  • Reoperation